![Mariah Lelos](https://profiles-cardiff.imgix.net/attachments/1099?w=200&h=200&auto=format&crop=faces&fit=crop&q=90")
Dr Mariah Lelos
(hi/ei)
- Ar gael fel goruchwyliwr ôl-raddedig
Timau a rolau for Mariah Lelos
Darllenydd
Ysgol y Biowyddorau
Trosolwyg
https://www.thebrainrepairgroup.com/
https://www.hdcentreinwales.com/
Rwy'n cyd-gyfarwyddo'r Grŵp Atgyweirio Ymennydd (BRG), lle rydym yn canolbwyntio ar ddeall a thrin clefydau niwroddirywiol, yn enwedig clefydau Parkinson a Huntington. Mae gennym ddiddordeb mewn deall amlygiad camweithrediadau echddygol ac an-echddygol (gwybyddol, niwroseiciatrig) mewn clefydau dirywiol gan ddefnyddio modelau lesion, fector firaol a chnofilod wedi'u haddasu'n enetig. Rydym hefyd yn ymchwilio i allu therapïau celloedd newydd (sy'n deillio o hESC a hiPSC) a therapïau genynnau i liniaru'r namau hyn ac yn optimeiddio'r triniaethau hyn ar gyfer cymhwysiad clinigol.
Rydw i:
Dirprwy Bennaeth yr Is-adran Niwrowyddoniaeth
PI cyswllt yn y Sefydliad Darganfod Meddyginiaethau (MDI) a chyd-I yn y Sefydliad Ymchwil Dementia (DRI)
Arweinydd Thema Cyswllt ar gyfer Meddwl, Ymennydd a Niwrowyddorau
Dirprwy Gadeirydd a Chynrychiolydd Biosi ar y Panel Lles Anifeiliaid ac Ymchwil (AWARP)
Aelod o Bwyllgor Gwaith y Ganolfan Niwrotherapiwteg Uwch
Arholwr Allanol yng Ngholeg y Brenin Llundain ar gyfer BSc Niwrowyddoniaeth a Seicoleg
Arweinydd Modiwl ar gyfer Niwrbioleg Anhwylderau'r Ymennydd
Cyhoeddiad
2026
- Lelos, M. J. 2026. Cell replacement therapy for neurodegenerative diseases 1. Available at: https://doi.org/10.69645/ohef9419.
- Lelos, M. J. 2026. Cell replacement therapy for neurodegenerative diseases 2. Available at: https://doi.org/10.69645/golr3762.
- Casella, C. et al. 2026. Differences in white matter detected by ex vivo 9.4 T MRI are associated with axonal changes in the R6/1 model of Huntington's disease. Neurobiology of Disease 220 107318. (10.1016/j.nbd.2026.107318)
- Barker, R. A. et al., 2026. The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.. Nature Biotechnology 44 , pp.70-78. (10.1038/s41587-025-02567-2)
2025
- Harrison, D. J. et al. 2025. Complex cognitive and motivational deficits precede motor dysfunction in the zQ175 (190 CAG repeat) Huntington's disease model.. Experimental Neurology 392 115350. (10.1016/j.expneurol.2025.115350)
- McLean, F. H. et al., 2025. Development of cognitive, motor, metabolic, and mutant huntingtin aggregation in the zQ175 mouse model of Huntington’s disease. Scientific Reports 15 (1) 34563. (10.1038/s41598-025-17956-5)
- Paisey, S. J. et al. 2025. Imaging of human stem cell-derived dopamine grafts correlates with behavioural recovery and reveals microstructural brain changes. Neurobiology of Disease 209 106910. (10.1016/j.nbd.2025.106910)
- Hakami, A. et al. 2025. Graft ischemia post cell transplantation to the brain: Glucose deprivation as the primary driver of rapid cell death. Neurotherapeutics 22 (2) e00518. (10.1016/j.neurot.2024.e00518)
2024
- Clark, B. J. , Lelos, M. J. and Loring, J. F. 2024. Advancing Parkinson’s disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells. Stem Cells 42 (9), pp.781-790. sxae042. (10.1093/stmcls/sxae042)
- Murillo, A. et al., 2024. I001 Cas9 nickase-mediated contraction of CAG repeats in Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry 95 (Suppl), pp.A141-A142. (10.1136/jnnp-2024-EHDN.283)
- Hennegan, J. et al., 2024. Inhibition of 7α,26-dihydroxycholesterol biosynthesis promotes midbrain dopaminergic neuron development. iScience 27 (1) 108670. (10.1016/j.isci.2023.108670)
2023
- Lelos, M. J. et al. 2023. Impaired cognitive and motor function are coincident with l -DOPA-induced dyskinesia in a model of Parkinson’s disease. Scientific Reports 13 17697. (10.1038/s41598-023-44869-y)
- Indrigo, M. et al., 2023. Nuclear ERK1/2 signaling potentiation enhances neuroprotection and cognition via Importinα1/KPNA2. EMBO Molecular Medicine 15 (11) e15984. (10.15252/emmm.202215984)
- Clinch, S. P. et al., 2023. Identification of the neural correlates underlying conflict resolution performance using a rodent analogue of the Stroop tests. Neuroscience 524 , pp.79-88. (10.1016/j.neuroscience.2023.05.024)
- Rees, D. et al., 2023. Acyl-ghrelin attenuates neurochemical and motor deficits in the 6-OHDA model of Parkinson’s Disease. Cellular and Molecular Neurobiology 43 , pp.2377-2384. (10.1007/s10571-022-01282-9)
- Hills, R. et al. 2023. Neurite outgrowth and gene expression profile correlate with efficacity of human induced pluripotent stem cell-derived dopamine neuron grafts. Stem Cells and Development 32 (13-14), pp.387-397. (10.1089/scd.2023.0043)
2022
- Jareno, P. G. et al., 2022. Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons. In: Lane, E. L. , Drew, C. and Lelos, M. J. eds. International Review of Neurobiology: Current Challenges in Cell Therapy for Neurodegenerative Diseases. Vol. 166, Elsevier. , pp.1-48. (10.1016/bs.irn.2022.09.003)
- Lelos, M. J. 2022. Investigating cell therapies in animal models of Parkinson's and Huntington's disease: current challenges and considerations. In: Lane, E. L. , Drew, C. and Lelos, M. J. eds. International Review of Neurobiology. Vol. 166, Elsevier. , pp.158-189. (10.1016/bs.irn.2022.09.005)
- Lane, E. L. and Lelos, M. J. 2022. Defining the unknowns for cell therapies in Parkinson's disease. Disease Models and Mechanisms 15 (10) dmm049543. (10.1242/dmm.049543)
- Murillo, A. et al., 2022. I05 CRISPR-Cas9 nickase-mediated gene editing to treat Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry 93 (Suppl) A86. (10.1136/jnnp-2022-ehdn.231)
- Sap, J. B. I. et al., 2022. [18F]Difluorocarbene for Positron Emission Tomography. Nature 606 , pp.102-108. (10.1038/s41586-022-04669-2)
- Lelos, M. J. 2022. Can cell and gene therapies improve cognitive symptoms in Parkinson's disease?. Journal of Integrative Neuroscience 21 (3) 78. (10.31083/j.jin2103078)
- Lane, E. L. et al. 2022. Spontaneous graft-induced dyskinesias are independent of 5-HT neurons and levodopa priming in a model of Parkinson's disease. Movement Disorders 37 (3), pp.613-619. (10.1002/mds.28856)
2021
- Bartley, O. J. M. et al. 2021. Do foetal transplant studies continue to be justified in Huntington's disease?. Neuronal Signaling 5 acerbic. (10.1042/NS20210019)
2020
- Lelos, M. 2020. Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases. In: Salgado, A. J. ed. Handbook of Innovations in Central Nervous System Regenerative Medicine. Elsevier. , pp.29-53. (doi.org/10.1016/B978-0-12-818084-6.00002-7)
2018
- Lelos, M. J. and Dunnett, S. B. 2018. Generating excitotoxic lesion models of Huntington’s Disease. In: Precious, S. V. , Rosser, A. E. and Dunnett, S. B. eds. Huntington’s Disease. Methods in Molecular Biology Vol. 1780.New York, NY, USA: , pp.209-220. (10.1007/978-1-4939-7825-0_11)
- Clinch, S. P. et al. 2018. Rethinking functional outcome measures: the development of an upper limb test to assess basal ganglia dysfunction. Frontiers in Neuroscience 12 366. (10.3389/fnins.2018.00366)
2017
- Kirkeby, A. et al., 2017. Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson's disease. Cell Stem Cell 20 (1), pp.135-148. (10.1016/j.stem.2016.09.004)
2016
- Yhnell, E. et al. 2016. L30 Cognitive training improves disease symptoms in a mouse model of huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry 87 (Supp 1), pp.A100-A101. (10.1136/jnnp-2016-314597.285)
- Yhnell, E. et al. 2016. Cognitive training modifies disease symptoms in a mouse model of Huntington's disease. Experimental Neurology 282 , pp.19-26. (10.1016/j.expneurol.2016.05.008)
- Harvey, A. K. et al., 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2 (2) 033. (10.23937/2469-5726/1510033)
- Lelos, M. et al. 2016. Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease. Experimental Neurology 278 , pp.54-61. (10.1016/j.expneurol.2016.02.003)
- Lelos, M. J. et al. 2016. Direct comparison of rat- and human-derived ganglionic eminence tissue grafts on motor function. Cell Transplantation 25 , pp.665-675. (10.3727/096368915X690297)
2014
- Lelos, M. J. and Good, M. A. 2014. β-Amyloid pathology alters neural network activation during retrieval of contextual fear memories in a mouse model of Alzheimer's disease. European Journal of Neuroscience 39 (10), pp.1690-1703. (10.1111/ejn.12527)
2013
- Murphy, E. M. et al. 2013. Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat. NeuroReport 24 (18), pp.1019-1024. (10.1097/WNR.0000000000000060)
- Carri, A. D. et al., 2013. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32(+) medium-sized spiny neurons. Development 140 (2), pp.301-312. (10.1242/dev.084608)
- Heuer, A. et al. 2013. Dopamine-rich grafts alleviate deficits in contralateral response space induced by extensive dopamine depletion in rats. Experimental Neurology 247 , pp.485-495. (10.1016/j.expneurol.2013.01.020)
- Lelos, M. J. et al. 2013. The lateral neostriatum is necessary for compensatory ingestive behaviour after intravascular dehydration in female rats. Appetite 71 , pp.287-294. (10.1016/j.appet.2013.09.003)
- Lelos, M. J. , Lane, E. and Dunnett, S. B. 2013. What helps can also hinder: A dissociation in the acute effect of levodopa treatment on motor and cognitive functions. Movement Disorders 28 (5), pp.563-564. (10.1002/mds.25294)
- Trueman, R. C. et al., 2013. Repair of the CNS using endogenous and transplanted neural stem cells. Current Topics in Behavioural Neurosciences 15 , pp.357-398. (10.1007/7854_2012_223)
2012
- Dunnett, S. B. et al. 2012. Bilateral striatal lesions disrupt performance in an operant delayed reinforcement task in rats. Brain Research Bulletin 88 (2-3), pp.251-260. (10.1016/j.brainresbull.2011.04.002)
- Heuer, A. et al. 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. Behavioural Brain Research 228 (1), pp.30-43. (10.1016/j.bbr.2011.11.027)
- Lelos, M. J. , Dowd, E. and Dunnett, S. B. 2012. Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible?. In: Progress in Brain Research. Vol. 200, Elsevier. , pp.113-142. (10.1016/B978-0-444-59575-1.00006-5)
- Lelos, M. J. and Good, M. A. 2012. c-Fos expression reveals aberrant neural network activity during cued fear conditioning in APPswe transgenic mice. Neurobiology of Learning and Memory 98 (1), pp.1-11. (10.1016/j.nlm.2012.03.001)
- Lelos, M. J. , Harrison, D. J. and Dunnett, S. B. 2012. Intrastriatal excitotoxic lesion or dopamine depletion of the neostriatum differentially impairs response execution in extrapersonal space. European Journal of Neuroscience 36 (10), pp.3420-3428. (10.1111/j.1460-9568.2012.08256.x)
- Lindgren, H. S. , Lelos, M. J. and Dunnett, S. B. 2012. Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?. Experimental Neurology 237 (1), pp.36-42. (10.1016/j.expneurol.2012.05.022)
2011
- Lelos, M. J. , Harrison, D. J. and Dunnett, S. B. 2011. Impaired sensitivity to Pavlovian stimulus-outcome learning after excitotoxic lesion of the ventrolateral neostriatum. Behavioural Brain Research 225 (2), pp.522-528. (10.1016/j.bbr.2011.08.017)
- Thomas, R. S. et al. 2011. Clathrin-mediated endocytic proteins are upregulated in the cortex of the Tg2576 mouse model of Alzheimer's disease-like amyloid pathology. Biochemical and Biophysical Research Communications 415 (4), pp.656-661. (10.1016/j.bbrc.2011.10.131)
- Lelos, M. J. et al. 2011. Outcome-specific satiety reveals a deficit in context-outcome, but not stimulus-or action-outcome, associations in aged Tg2576 mice. Behavioral Neuroscience 125 (3), pp.412-425. (10.1037/a0023415)
- Lelos, M. J. and Dunnett, S. B. 2011. Aberrant dopamine transmission and cognitive dysfunction in animal models of Parkinson's disease. Journal of Parkinson's Disease 1 (2), pp.151-165.
2010
- Dunnett, S. B. and Lelos, M. 2010. Behavioural analysis of motor and non-motor symptoms in rodent models of Parkinson’s disease. In: Progress in Brain Research. Vol. 184, Elsevier. , pp.35-51. (10.1016/S0079-6123(10)84003-8)
- Lelos, M. J. 2010. Influence of beta-amyloid pathology on emotional learning and memory in the APPswe model of Alzheimer's disease. PhD Thesis , Cardiff University.
Adrannau llyfrau
- Jareno, P. G. et al., 2022. Challenges in progressing cell therapies to the clinic for Huntington's disease: A review of the progress made with pluripotent stem cell derived medium spiny neurons. In: Lane, E. L. , Drew, C. and Lelos, M. J. eds. International Review of Neurobiology: Current Challenges in Cell Therapy for Neurodegenerative Diseases. Vol. 166, Elsevier. , pp.1-48. (10.1016/bs.irn.2022.09.003)
- Lelos, M. J. 2022. Investigating cell therapies in animal models of Parkinson's and Huntington's disease: current challenges and considerations. In: Lane, E. L. , Drew, C. and Lelos, M. J. eds. International Review of Neurobiology. Vol. 166, Elsevier. , pp.158-189. (10.1016/bs.irn.2022.09.005)
- Lelos, M. 2020. Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases. In: Salgado, A. J. ed. Handbook of Innovations in Central Nervous System Regenerative Medicine. Elsevier. , pp.29-53. (doi.org/10.1016/B978-0-12-818084-6.00002-7)
- Lelos, M. J. and Dunnett, S. B. 2018. Generating excitotoxic lesion models of Huntington’s Disease. In: Precious, S. V. , Rosser, A. E. and Dunnett, S. B. eds. Huntington’s Disease. Methods in Molecular Biology Vol. 1780.New York, NY, USA: , pp.209-220. (10.1007/978-1-4939-7825-0_11)
- Lelos, M. J. , Dowd, E. and Dunnett, S. B. 2012. Nigral grafts in animal models of Parkinson's disease. Is recovery beyond motor function possible?. In: Progress in Brain Research. Vol. 200, Elsevier. , pp.113-142. (10.1016/B978-0-444-59575-1.00006-5)
- Dunnett, S. B. and Lelos, M. 2010. Behavioural analysis of motor and non-motor symptoms in rodent models of Parkinson’s disease. In: Progress in Brain Research. Vol. 184, Elsevier. , pp.35-51. (10.1016/S0079-6123(10)84003-8)
Erthyglau
- Casella, C. et al. 2026. Differences in white matter detected by ex vivo 9.4 T MRI are associated with axonal changes in the R6/1 model of Huntington's disease. Neurobiology of Disease 220 107318. (10.1016/j.nbd.2026.107318)
- Barker, R. A. et al., 2026. The TransEuro open-label trial of human fetal ventral mesencephalic transplantation in patients with moderate Parkinson's disease.. Nature Biotechnology 44 , pp.70-78. (10.1038/s41587-025-02567-2)
- Harrison, D. J. et al. 2025. Complex cognitive and motivational deficits precede motor dysfunction in the zQ175 (190 CAG repeat) Huntington's disease model.. Experimental Neurology 392 115350. (10.1016/j.expneurol.2025.115350)
- McLean, F. H. et al., 2025. Development of cognitive, motor, metabolic, and mutant huntingtin aggregation in the zQ175 mouse model of Huntington’s disease. Scientific Reports 15 (1) 34563. (10.1038/s41598-025-17956-5)
- Paisey, S. J. et al. 2025. Imaging of human stem cell-derived dopamine grafts correlates with behavioural recovery and reveals microstructural brain changes. Neurobiology of Disease 209 106910. (10.1016/j.nbd.2025.106910)
- Hakami, A. et al. 2025. Graft ischemia post cell transplantation to the brain: Glucose deprivation as the primary driver of rapid cell death. Neurotherapeutics 22 (2) e00518. (10.1016/j.neurot.2024.e00518)
- Clark, B. J. , Lelos, M. J. and Loring, J. F. 2024. Advancing Parkinson’s disease treatment: cell replacement therapy with neurons derived from pluripotent stem cells. Stem Cells 42 (9), pp.781-790. sxae042. (10.1093/stmcls/sxae042)
- Murillo, A. et al., 2024. I001 Cas9 nickase-mediated contraction of CAG repeats in Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry 95 (Suppl), pp.A141-A142. (10.1136/jnnp-2024-EHDN.283)
- Hennegan, J. et al., 2024. Inhibition of 7α,26-dihydroxycholesterol biosynthesis promotes midbrain dopaminergic neuron development. iScience 27 (1) 108670. (10.1016/j.isci.2023.108670)
- Lelos, M. J. et al. 2023. Impaired cognitive and motor function are coincident with l -DOPA-induced dyskinesia in a model of Parkinson’s disease. Scientific Reports 13 17697. (10.1038/s41598-023-44869-y)
- Indrigo, M. et al., 2023. Nuclear ERK1/2 signaling potentiation enhances neuroprotection and cognition via Importinα1/KPNA2. EMBO Molecular Medicine 15 (11) e15984. (10.15252/emmm.202215984)
- Clinch, S. P. et al., 2023. Identification of the neural correlates underlying conflict resolution performance using a rodent analogue of the Stroop tests. Neuroscience 524 , pp.79-88. (10.1016/j.neuroscience.2023.05.024)
- Rees, D. et al., 2023. Acyl-ghrelin attenuates neurochemical and motor deficits in the 6-OHDA model of Parkinson’s Disease. Cellular and Molecular Neurobiology 43 , pp.2377-2384. (10.1007/s10571-022-01282-9)
- Hills, R. et al. 2023. Neurite outgrowth and gene expression profile correlate with efficacity of human induced pluripotent stem cell-derived dopamine neuron grafts. Stem Cells and Development 32 (13-14), pp.387-397. (10.1089/scd.2023.0043)
- Lane, E. L. and Lelos, M. J. 2022. Defining the unknowns for cell therapies in Parkinson's disease. Disease Models and Mechanisms 15 (10) dmm049543. (10.1242/dmm.049543)
- Murillo, A. et al., 2022. I05 CRISPR-Cas9 nickase-mediated gene editing to treat Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry 93 (Suppl) A86. (10.1136/jnnp-2022-ehdn.231)
- Sap, J. B. I. et al., 2022. [18F]Difluorocarbene for Positron Emission Tomography. Nature 606 , pp.102-108. (10.1038/s41586-022-04669-2)
- Lelos, M. J. 2022. Can cell and gene therapies improve cognitive symptoms in Parkinson's disease?. Journal of Integrative Neuroscience 21 (3) 78. (10.31083/j.jin2103078)
- Lane, E. L. et al. 2022. Spontaneous graft-induced dyskinesias are independent of 5-HT neurons and levodopa priming in a model of Parkinson's disease. Movement Disorders 37 (3), pp.613-619. (10.1002/mds.28856)
- Bartley, O. J. M. et al. 2021. Do foetal transplant studies continue to be justified in Huntington's disease?. Neuronal Signaling 5 acerbic. (10.1042/NS20210019)
- Clinch, S. P. et al. 2018. Rethinking functional outcome measures: the development of an upper limb test to assess basal ganglia dysfunction. Frontiers in Neuroscience 12 366. (10.3389/fnins.2018.00366)
- Kirkeby, A. et al., 2017. Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson's disease. Cell Stem Cell 20 (1), pp.135-148. (10.1016/j.stem.2016.09.004)
- Yhnell, E. et al. 2016. L30 Cognitive training improves disease symptoms in a mouse model of huntington's disease. Journal of Neurology, Neurosurgery & Psychiatry 87 (Supp 1), pp.A100-A101. (10.1136/jnnp-2016-314597.285)
- Yhnell, E. et al. 2016. Cognitive training modifies disease symptoms in a mouse model of Huntington's disease. Experimental Neurology 282 , pp.19-26. (10.1016/j.expneurol.2016.05.008)
- Harvey, A. K. et al., 2016. Novel application of behavioral assays allows dissociation of joint pathology from systemic extra-articular alterations induced by inflammatory arthritis. Journal of Rheumatic Diseases and Treatment 2 (2) 033. (10.23937/2469-5726/1510033)
- Lelos, M. et al. 2016. Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease. Experimental Neurology 278 , pp.54-61. (10.1016/j.expneurol.2016.02.003)
- Lelos, M. J. et al. 2016. Direct comparison of rat- and human-derived ganglionic eminence tissue grafts on motor function. Cell Transplantation 25 , pp.665-675. (10.3727/096368915X690297)
- Lelos, M. J. and Good, M. A. 2014. β-Amyloid pathology alters neural network activation during retrieval of contextual fear memories in a mouse model of Alzheimer's disease. European Journal of Neuroscience 39 (10), pp.1690-1703. (10.1111/ejn.12527)
- Murphy, E. M. et al. 2013. Long-term restorative effects of bromocriptine on operant responding in the 6-hydroxydopamine-lesioned rat. NeuroReport 24 (18), pp.1019-1024. (10.1097/WNR.0000000000000060)
- Carri, A. D. et al., 2013. Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32(+) medium-sized spiny neurons. Development 140 (2), pp.301-312. (10.1242/dev.084608)
- Heuer, A. et al. 2013. Dopamine-rich grafts alleviate deficits in contralateral response space induced by extensive dopamine depletion in rats. Experimental Neurology 247 , pp.485-495. (10.1016/j.expneurol.2013.01.020)
- Lelos, M. J. et al. 2013. The lateral neostriatum is necessary for compensatory ingestive behaviour after intravascular dehydration in female rats. Appetite 71 , pp.287-294. (10.1016/j.appet.2013.09.003)
- Lelos, M. J. , Lane, E. and Dunnett, S. B. 2013. What helps can also hinder: A dissociation in the acute effect of levodopa treatment on motor and cognitive functions. Movement Disorders 28 (5), pp.563-564. (10.1002/mds.25294)
- Trueman, R. C. et al., 2013. Repair of the CNS using endogenous and transplanted neural stem cells. Current Topics in Behavioural Neurosciences 15 , pp.357-398. (10.1007/7854_2012_223)
- Dunnett, S. B. et al. 2012. Bilateral striatal lesions disrupt performance in an operant delayed reinforcement task in rats. Brain Research Bulletin 88 (2-3), pp.251-260. (10.1016/j.brainresbull.2011.04.002)
- Heuer, A. et al. 2012. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites. Behavioural Brain Research 228 (1), pp.30-43. (10.1016/j.bbr.2011.11.027)
- Lelos, M. J. and Good, M. A. 2012. c-Fos expression reveals aberrant neural network activity during cued fear conditioning in APPswe transgenic mice. Neurobiology of Learning and Memory 98 (1), pp.1-11. (10.1016/j.nlm.2012.03.001)
- Lelos, M. J. , Harrison, D. J. and Dunnett, S. B. 2012. Intrastriatal excitotoxic lesion or dopamine depletion of the neostriatum differentially impairs response execution in extrapersonal space. European Journal of Neuroscience 36 (10), pp.3420-3428. (10.1111/j.1460-9568.2012.08256.x)
- Lindgren, H. S. , Lelos, M. J. and Dunnett, S. B. 2012. Do alpha-synuclein vector injections provide a better model of Parkinson's disease than the classic 6-hydroxydopamine model?. Experimental Neurology 237 (1), pp.36-42. (10.1016/j.expneurol.2012.05.022)
- Lelos, M. J. , Harrison, D. J. and Dunnett, S. B. 2011. Impaired sensitivity to Pavlovian stimulus-outcome learning after excitotoxic lesion of the ventrolateral neostriatum. Behavioural Brain Research 225 (2), pp.522-528. (10.1016/j.bbr.2011.08.017)
- Thomas, R. S. et al. 2011. Clathrin-mediated endocytic proteins are upregulated in the cortex of the Tg2576 mouse model of Alzheimer's disease-like amyloid pathology. Biochemical and Biophysical Research Communications 415 (4), pp.656-661. (10.1016/j.bbrc.2011.10.131)
- Lelos, M. J. et al. 2011. Outcome-specific satiety reveals a deficit in context-outcome, but not stimulus-or action-outcome, associations in aged Tg2576 mice. Behavioral Neuroscience 125 (3), pp.412-425. (10.1037/a0023415)
- Lelos, M. J. and Dunnett, S. B. 2011. Aberrant dopamine transmission and cognitive dysfunction in animal models of Parkinson's disease. Journal of Parkinson's Disease 1 (2), pp.151-165.
Fideos
- Lelos, M. J. 2026. Cell replacement therapy for neurodegenerative diseases 1. Available at: https://doi.org/10.69645/ohef9419.
- Lelos, M. J. 2026. Cell replacement therapy for neurodegenerative diseases 2. Available at: https://doi.org/10.69645/golr3762.
Gosodiad
- Lelos, M. J. 2010. Influence of beta-amyloid pathology on emotional learning and memory in the APPswe model of Alzheimer's disease. PhD Thesis , Cardiff University.
Ymchwil
https://www.thebrainrepairgroup.com/
Rwy'n gyd-gyfarwyddwr y Brain Repair Group. Mae ein labordy yn canolbwyntio ar ddeall a thrin clefydau niwroddirywiol, yn enwedig clefydau Parkinson a Huntington. Mae gennym ddiddordeb mewn deall amlygiad diffygion echddygol a di-fodur (gwybyddol, niwroseiciatreg) mewn clefydau dirywiol gan ddefnyddio briwiau, fector firaol a modelau cnofilod a addaswyd yn enetig. Rydym hefyd yn ymchwilio i allu celloedd newydd (hESC- a hiPSC-deillio) a therapïau genynnau i leddfu'r namau hyn a gwneud y gorau o'r triniaethau hyn i'w cymhwyso yn glinigol.
Mae rhai cwestiynau ymchwil cyfredol sy'n cael eu trafod yn cynnwys:
A all impiadau dopamin sy'n deillio o HPC leddfu camweithrediadau nad ydynt yn motor mewn clefyd Parkinson?
A yw neuroinflammation yn chwarae rhan mewn dyskinesias a achosir gan domines sy'n deillio o HPC?
Beth yw effaith cynhyrchu dopamin o fectorau AAV ar swyddogaeth wybyddol sy'n ddibynnol ar striatal?
A allwn ni fodiwleiddio mynegiant genynnau i wella twf allan niwrite a ffurfio synapse o impiadau dopamin sy'n deillio o HPC?
A all trawsblaniadau niwronau troellog canolig sy'n deillio o HPC ffurfio cysylltiadau synaptig a lliniaru camweithrediadau nad ydynt yn foduron mewn modelau o glefyd Huntingtons?
Addysgu
Ar hyn o bryd rwy'n Arweinydd Modiwl ar y modiwl 3ydd flwyddyn BI3451 'Niwrobioleg Anhwylderau'r Ymennydd'.
Rwyf hefyd yn dysgu ar:
DET044 Bôn-gelloedd a Meddygaeth Adfywiol, sy'n rhan o'r MSc mewn Peirianneg Meinweoedd
MET923 Imiwnomodulation y System Imiwnedd mewn Clefydau Cymhleth, sy'n rhan o'r MSc Imiwnoleg Glinigol Gymhwysol ac Arbrofol.
Rwy'n rhedeg ymarfer wythnos o hyd i ddysgu profion histolegol ac imiwnohistocemegol a sgiliau microsgopeg gan ddefnyddio meinweoedd ymennydd cnofilod.
Rwy'n diwtor personol ar gyfer myfyrwyr israddedig Niwrowyddoniaeth a Biofeddygol.
Gweler sgwrs ddiweddar ar fy maes:
- Lelos, MJ (2022, Ionawr 31). Therapi amnewid celloedd ar gyfer clefydau niwroddirywiol [Ffeil fideo]. Yn y Casgliad Biofeddygol a Gwyddorau Bywyd, Henry Stewart Talks. Cyrchwyd Mawrth 22, 2022, o https://hstalks.com/bs/4882/.
Bywgraffiad
Ymchwiliodd fy PhD (2005-2010, yr Athro M Da) gamweithrediad rhwydwaith niwral gan ddefnyddio modelu mathemategol mewn model llygoden o glefyd Alzheimer, gyda ffocws penodol ar gamweithrediad a achosir gan amyloid yn y ffurfiad amydala a hippocampal.
Nod fy ymchwil ôl-ddoethurol (2010-2015, yr Athro S Dunnett) oedd deall camweithrediad ganglia sylfaenol ym mhwyster Parkinson a Huntington ac archwilio'r defnydd o therapïau sy'n deillio o gelloedd ffetws dynol a bôn-gelloedd newydd i leddfu'r namau ymddygiadol.
Dyfarnwyd Uwch Gymrodoriaeth Ymchwil i mi gan Parkinson's UK (2015-2018) i ymchwilio i allu cynhyrchion therapi celloedd bôn-gelloedd dynol i leddfu namau gwybyddol mewn modelau cnofilod o glefyd Parkinson.
Wedi hynny dechreuais Uwch Ddarlithyddiaeth yn yr adran niwrowyddoniaeth a dyrchafiad yn Ddarllenydd yn 2024. Mae fy labordy yn archwilio sawl llwybr newydd. Rydym yn ceisio sefydlu therapïau celloedd newydd i drin clefydau Huntington, gan ddefnyddio triniaethau DREADDs newydd i ddeall mecanwaith gweithredu therapïau celloedd, ymgymryd â delweddu PET/MR a defnyddio technolegau olrhain gynddaredd i archwilio integreiddio synaptig. Rydym hefyd yn astudio effaith therapïau genynnau newydd ar swyddogaeth gellog ac ar gamweithrediad gwybyddol.
Meysydd goruchwyliaeth
Rwy'n awyddus i groesawu myfyrwyr PhD newydd i'r tîm sydd â diddordeb penodol yn:
Clefyd Parkinson
Clefyd Huntington
Diffygion gwybyddol neu niwroseiciatrig
Therapïau celloedd
Therapïau genynnau
Goruchwyliaeth gyfredol
Prosiectau'r gorffennol
Myfyrwyr PhD blaenorol:
Dr. Ellen Murphy: Effeithiau triniaeth dopaminergig acíwt a chronig ar swyddogaeth echddygol a di-fodur yn y llygoden fawr hemi-Parkinsonaidd
Dr. Susanne Clinch: Datblygu a gwerthuso tasgau ymddygiadol i asesu swyddogaeth ganglia sylfaenol
Cân Dr. Mengru: A yw levodopa yn effeithio ar oroesi niwronau dopaminergig mewndarddol ac ecsogenous?
Dr. Charlotte Bridge: Ymchwilio i rôl dopamin mewn namau gwybyddol mewn model llygod mawr o glefyd Parkinson
Dr. Patricia Garcia Jareno: Ymchwilio i integreiddio gweithredol impiadau sy'n deillio o hESC yng nghlwy'r Huntington
Dr. Feras Sharouf: Optimeiddio darpariaeth a goroesiad therapïau celloedd mewn clefyd Huntington
Dr. Rachel Spicer (Sellick gynt): Dadansoddiad o ryngweithio genetig a phrotein sy'n gysylltiedig â dirywiad a achosir gan helfeydd mutant
Myfyrwyr MPhil blaenorol:
Rachel Hills (MPhil): Nodweddu a chymharu cynhyrchion therapi celloedd sy'n deillio o gleifion mewn model clefyd Parkinson cyn-glinigol
Myfyrwyr Meistr blaenorol:
Ammar Alsulaimi: Effaith Proxison, gwrthocsidydd newydd wedi'i dargedu gan mitochondrial, ar oroesiad niwronau dopamin wedi'u trawsblannu mewn model llygod mawr o glefyd Parkinson
Daniel Dabbs: Dadansoddiad imiwnohistocemegol o iPSCs sy'n deillio o gleifion ar gyfer trawsblannu mewn clefyd Parkinson
Eldad Eradiri: Ymchwilio i effaith oedran meinwe rhoddwyr a pharatoi ar oroesiad ac effeithiolrwydd trawsblaniadau estryal-ffetws dynol cyn-glinigol
Emily Stonelake: Ymchwilio i effaith impiadau dopaminergic bôn-gelloedd embryonig dynol ar swyddogaeth nad yw'n fodurol mewn model cnofilod o glefyd Parkinson
Gareth Williams: Therapi genynnau ar gyfer clefyd Parkinson: yr effaith ar namau gwybyddol
Issac Mondon: Newidiadau i fater gwyn mewn clefyd Huntington cyn-symptomatig gan ddefnyddio modelau llygod R6/1
Jeremie Costales: Effeithiau Levodopa ar oroesiad bôn-gelloedd embryonig dynol trawsblannu (hESC) impiadau mewn llygod mawr 6-OHDA
Joanne Lachica: Gwerthusiad ymateb dos o fector firaol newydd sy'n gysylltiedig ag adeno ar gyfer amnewid dopamin mewn model 6-hydroxydopamin o glefyd Parkinson
Laura Clark: Characterising FoxP1 mynegiant yn y modelau llygoden R6/1 a Q150 HD dros amser
Olivia Edwards: Rwy'nmmunohistochemical dadansoddiad o niwroglia mewn llygod mawr Parkinsonaidd wedi'u trawsblannu â chell dopamin dynol
Phoebe Norton: Mae Xav yn nodi'r fan a'r lle: asesu'r defnydd o ataliad Wnt mewn therapi celloedd ar gyfer clefyd Huntington
Demi Owen-Bowyer: Sefydlu biofarcwyr a throthwyon diogelwch ar gyfer gordyfiant niwral a tumorigenesis mewn niwronau troellog canolig sy'n deillio o fôn-gelloedd embryonig dynol
News articles
Contact Details
+44 29208 75541
Adeilad Syr Martin Evans, Ystafell Cardiff School of Biosciences, The Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX, Rhodfa'r Amgueddfa, Caerdydd, CF10 3AX
Themâu ymchwil
Arbenigeddau
- Clefyd Parkinson
- Clefyd Huntington
- Therapïau celloedd
- Therapïau genynnau
- Gwybyddiaeth
